INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Other EventsItem 8.01 Other Events.
On September19, 2017, GlaxoSmithKline plc (“GSK”) and Innoviva,Inc. (Innoviva) distributed a press release announced positive headline results from the phase III InforMing the PAthway of COPD Treatment (IMPACT) study of Trelegy Ellipta, the first and only once-daily single inhaler triple therapy comprising an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA) and long-action beta agonist (LABA) approved by the U.S. Food and Drug Administration (“FDA”).
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI) is approved by the FDA for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema, who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations, in whom additional treatment of airflow obstruction is desired or patients who are on umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol.
The press release is filed as Exhibit99.1 to this report and is incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
Press Release dated September19, 2017